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ABSTRACT
Nissen and Bullemer (1987) developed the serial reaction time (SRT) task to measure
attention in humans. The SRT task in rats is typically modeled after studies with humans
and uses repeated or random sequences to test anticipatory reactions. In the current study,
paraquat (PQ)-induced Parkinson‟s disease (PD) model in Long-Evans hooded rats was
used to examine the rats‟ sequential learning. A water-soluble formulation of coenzyme
Q10 (WS- CoQ10) was used as a therapeutic agent. Rats were induced with Parkinson‟s
disease via the administration of paraquat. The aim of this study was to study the
neuroprotective effects of CoQ10 using the SRT task to measure sequence performance in
rats. The results indicated that the rats were much faster in responding to fixed sequences
compared to random sequences. However, this study did not find significant results to
indicate that exposure of paraquat with or without a neuroprotective agent, WS-CoQ10
affected serial reaction performance. The implications of these findings are discussed
with suggestions for further research with this task.
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CHAPTER I
INTRODUCTION
One of the common motor disorders affecting between 80,000 to 100,000
Canadians is Parkinson‟s disease (PD), which results in the loss of dopamine-producing
brain cells present in the substantia nigra pars compacta region of the brain. Much of the
information regarding the etiology and pathogenesis of PD has been obtained from
clinical, postmortem and epidemiological studies. Currently, the goals of therapy in PD
are to maintain function and quality of life by treating its symptoms while trying to avoid
or minimize any drug-induced complications. To date, levodopa is the most effective
treatment for symptom relief in PD. The aim of all dopaminergic strategies is to restore
dopamine transmission in the striatum which is accomplished by stimulating postsynaptic
receptors (directly with dopamine agonists), increasing dopamine precursor availability
(levodopa), blocking the metabolism of levodopa in the brain, and blocking the
catabolism of dopamine at the presynaptic terminal. Treatment however, does not reverse
the morphologic changes and fails to arrest the progression of the disease. As the disease
progresses, drug therapies tend to become less effective and symptoms become more
difficult to manage. Thus the priority must be to move beyond symptom control and
develop neuroprotective therapies. Unfortunately, no such therapy is currently available,
leaving this area open for further research.
To make a model of neurodegeneration functionally relevant, a behavioural
component is necessary. Along with various motor gaiting and balancing tasks, the serial
reaction time task (SRT) may prove to be one of the most important assessment tools as it
combines motor function skills with attentional and other cognitive capacities. The SRT
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task consists of a sequence of a connected series of events that engages processes
supporting the temporal organization of behaviour, the formation of high-order
associations, and the prediction of future events (Chafee & Ashe, 2007; Keele et al.,
2004). Moreover this test is easy to administer and manipulated to assess a patient‟s
attention and other cognitive abilities as a function of the type and severity of his/her
neurodegenerative disorder. Despite such advantages, many inconsistent findings have
been reported from studies employing this test on human patients with PD. The use of
different samples of patient populations at uncontrolled different stages of the disease
have made comparisons between studies for replication of effects difficult to obtain.
Therefore developing animal models has become imperative to (a) better understand of
the pathogenesis of PD and for (b) preclinical testing of possible neuroprotective
therapeutics to treat PD. Moreover, in animal models, it may be easier to control the
degeneration of dopamine neurons with dose-specific exposure to neurotoxins like
paraquat. Rodents are a common choice of animal used to study PD, they have a short life
span and comparative brain structures with humans. In the neurological sciences, rodents
have proved to be an important tool for the study of neural development, diseases,
neurodegeneration, addiction, and general principles of cognitive behaviour. Given that
rodents are a common choice of animal model to investigate neurodegeneration, we
sought to use an SRT preparation derived from Eckart et al. (2010), who reported specific
effects on SRT performance from lesions to dopamine areas of the rat‟s brain.
Recent studies suggest that PD may arise from a combination of genetic
susceptibility and exposure to environmental toxins (McCormack et al., 2002). Several
environmental risk factors such as metals and herbicides have been linked to the greater
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incidence and progression of PD (Dinis-Oliveira et al., 2006). Among these factors, the
herbicide paraquat (PQ) shows a clear neurotoxicity in the central nervous system (CNS).
Sub-lethal doses of this toxin have been shown to have targeted effects on dopamine
neurons in the substantia nigra. PQ was chosen as the toxin to induce Parkinsonism in the
current study because it is an environmental toxin associated with increased incidence of
PD in areas where it has been used in agriculture (Liou et al. 1997) and also because it‟s
chemical structure is similar to that of the synthetic narcotic MPTP (1-methyl-4-phenyl-1,
2, 3, 6-tetrahydropyridine) known to have neuro-degenerative effects in the substantia
nigra pars compacta (SNc) (Norris et al. 2007). Consideration of PQ as a candidate
neurotoxicant requires that systemic delivery not only produces dopamine (DA) neuron
loss in the substantia niagra (SN) but also exhibits the resultant behavioural effects
reflecting dopamine depletion.
CoQ10 is known to be a powerful antioxidant that reduces oxidative stress in invitro preparations (Beal, 2003b). This in-vitro neuroprotectant has recently been shown to
have an in-vivo prophylactic effect in rats exposed to PQ and therefore might also have a
post-exposure therapeutic effect. This possibility could lead to important clinical
applications for preventing further loss of dopamine producing neurons in human PD
patients. Therefore the major goals of the current study are (a) to examine signal
sequence factors that affect rats‟ SRT performance, (b) to determine how such
performance is affected by rats‟ exposure to PQ, and (c) to determine whether post-PQ
exposure treatment with CoQ10 can ameliorate any SRT behavioral changes. We note
that this experiment is part of a larger preclinical study on the therapeutic effects of
CoQ10 conducted in the University of Windsor‟s biochemistry department by Facecchia
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et al. who are carrying out the biochemical assays on the brain tissue of these animals
following our laboratory‟s behavioural assessments.
In the next chapter, we discuss in further detail rats‟ serial pattern learning, PD
and animal models of this disorder, and mechanisms of neuroprotection by CoQ10.
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CHAPTER II
REVIEW OF LITERATURE
Parkinson’s Disease
Epidemiology
Parkinson‟s disease (PD) is one of the most common degenerative disorders of the
nervous system. Occurring in about 1% of people over the age of 65, its peak age of onset
is in the 60s (range is 35 to 85 years) and the course of the illness ranges between 10 and
25 years (Kasper et al., 2005). Familial clusters of autosomal dominant and recessive
forms of PD comprise approximately 5% of cases (Cory-Slechta et al., 2005). These
cases are characterized by an earlier age of onset (typically before age 50) and a longer
course than the more typical sporadic PD.
Clinical Features
An accurate diagnosis of PD can usually be made (with some confidence) in
patients who present with rest tremor, rigidity and bradykinesia. Tremor is particularly
important because it is found in 85% of patients with PD (Kasper et al., 2005). A
unilateral and gradual onset of symptoms further supports the diagnosis. Masked faces,
decreased eye blinking, stooped posture and decreased arm swing are some of the early
symptoms of this disease. The most disabling feature of PD is bradykinesia, which
interferes with all aspects of daily living. Fine motor control is also impaired as noted by
a decrease in manual dexterity and handwriting (micrographia). Rest tremor typically
appears unilaterally, first distally, involving the digits and wrist, where it may have a “pill
rolling” character. Tremor usually spreads proximally, ipsilaterally and occasionally to
the leg before crossing to the other side after a year or more after the onset of the disease.
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Tremor may later appear in the lips, tongue and jaw. Rigidity is felt as a uniform
resistance to passive movement about a joint throughout the full range of motion, giving
rise to a characteristic “plastic” quality. Short lived and regular interruptions of resistance
during passive movement may give rise to a “cogwheeling” sensation.
Gait disturbance with shuffling and short steps is a prominent feature of PD.
Festinating gait is a classic Parkinsonian sign and results from the combination of flexed
posture and loss of postural reflexes which in turn cause the patient to accelerate in an
effort to “catch up” with the body‟s center of gravity. Freezing of gait, a feature of more
advanced PD, commonly occurs at the onset of locomotion (start hesitation), when
attempting to change direction or turn around, and upon entering a narrow space. Postural
instability is one of the most disabling features of advanced PD, contributing to falls and
injuries and leading to major morbidity and mortality in this population.
Non motor aspects of PD include depression, anxiety, cognitive impairment, sleep
disturbances, sensory abnormalities and pain, loss of smell (anosmia), and disturbances of
autonomic function. Together they may contribute as much to the burden of the disease
as the more obvious motor abnormalities.
Pathology
On gross pathologic exam, the typical macroscopic findings in a PD brain are
pallor of the substantia nigra and locus ceruleus due to degeneration of dopamineproducing neurons in the substantia nigra pars compacta (SNc), a region within the
midbrain (Corti et al., 2005). As mentioned previously, PD exhibits four classic
symptoms: a resting tremor, muscular rigidity or stiffness, an inability to initiate
movement, and generalized slowness of movement and postural instability. These
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symptoms become fully developed after approximately 80% of the dopaminergic neurons
in the SN are already lost, resulting in reduced synthesis and release of DA from the SNc
region (Schober, 2004). Pharmacologic restoration of dopamine transmission is thus the
basis for symptomatic drug treatment of PD.
PD is assumed to be a multicentric disease. It is also believed that an association
exists between the nigrostriatal degeneration and degenerative processes elsewhere in the
central and peripheral nervous systems. Three possible mechanisms are hypothesized:
damage to the SNc and other regions occurs simultaneously; the disease primarily begins
in the SNc, which influences the involvement of other areas; or the involvement of the
SNc occurs later in the disease (Lang & Lozano, 1998). Associated with this neuronal
loss is the presence of large eosinophilic inclusions called “Lewy bodies,” which are
found in the cytoplasm of the surviving neurons in the SN region. Lewy bodies are single
or multiple, intracytoplasmic, eosinophilic round to elongated inclusions that often have a
dense core surrounded by a pale halo (Cotran et al., 1999). They are abnormal aggregates
made up of a series of proteins including neurofilaments, -synuclein fibrils, ubiquitin,
parkin, and proteasomal elements and are a hallmark of genetic diseases such as PD
(Schapira, 1999).
Basal Ganglia
Control of movement is highly varied in humans, from manipulating objects as
light as a needle to swinging objects as heavy as a baseball bat to drive a ball across a
field. Parkinson‟s disease (PD) is a disorder of “controlling” movements (Kolb, 2001).
The brain areas that allow us to adjust the force of our movements include the basal
ganglia (BG), which are a group of nuclei situated at the base of the forebrain and are
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connected with the cerebral cortex, thalamus and other brain areas. The BG has two
subdivisions: (i) the rostral subdivision, containing the striatum (putamen and caudate
nucleus), pas externa (GPe), and pars internal (GPi) segments of the globus pallidus; and
(ii) the caudal subdivision, containing the subthalamic nucleus (STN) and the substantia
nigra (SN), which encompasses the SN pars compacta (SNc), SN pars reticulate (SNr)
and the SN pars lateralis (SNI) (Obaso et al., 2008) (Figure 1). The BG are associated
with a variety of functions, including voluntary motor control, procedural learning
relating to routing behaviours, or “habits”, eye movements and most importantly,
cognitive and emotional functions. In particular, the motor circuit has two entry points
into the BG, the striatum and the STN, and an output, the GPi, which connects to the
cortex via the motor thalamus (Obaso et al., 2008). The signals for intentional movements
are initiated in the cerebral motor cortex and eventually reach the brain stem. From the
brain stem the signals are transmitted to the muscles. Before this they reach the muscles,
centers such as the cerebellum and the basal ganglia pose their influence on these signals.
Both of these centers exert their influence on the final motor signals via the thalamus
(Groenewegen, 2003). One theory holds that an inhibitory pathway and an excitatory
pathway affect the activity of the motor cortex: (Alexander & Crutcher, 1990). Both these
pathways converge on an area of the basal ganglia called the internal path of the globus
pallidus (GPi). The GPi in turn, projects into the ventral thalamic nucleus and the
thalamus projects to the motor cortex. The thalamic projections determine the size or
force of a movement that the cortex produces and is influenced by the GPi. The GPi acts
metaphorically like the volume dial on a radio because it controls the output thereby
dictating whether a movement will be strong or weak. The direct projections to the GPi
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are via the striatum and STN. Neurons in this pathway are the D1 dopamine receptor
subtype and they provide a direct inhibitory effect on the GPi/SNr (Figure 2A). The
indirect projections to the GPi are via the GPe. Neurons in this pathway are the D2
dopamine receptor subtype, which cause the excitation of GPi/SNr (Figure 2B). The GPe
regulates the motor output of the BG (Obaso, 2008). The output from the basal ganglia is
influenced by the opposing effects of the direct and indirect pathways. If the activity in
the indirect pathway dominates, the thalamus shuts down, and the cortex is unable to
produce movement. If direct-pathway activity dominates, the thalamus can become
overactive thereby amplifying the movements (Kolb, 2006). The DA deficiency that
precedes PD leads to a cascade of functional changes in basal ganglia circuitry.
Dopamine modifies striatal input and neuronal striatal activity, modulated GPe and GPi,
and STN activity. The loss of DA neurons in PD disrupts the corticostriatal balance,
which increases activity in the indirect circuit and ultimately reduces the activity in the
direct circuit (Obaso, 2008). Therefore, PD is characterized by increased neuronal
activity in the STN, GPi and SNr regions, leading to an inhibition of motor nuclei, which
regulate the body‟s ability to execute smooth and controlled movements.
Dopamine Pathways
Dopamine (DA) is a catecholamine neurotransmitter present in all animals and
readily available in the substantia nigra (SN). Dopamine has many functions in the brain;
among them are vital roles in cognition, voluntary movement, motivation, punishment
and reward. Dopamine is produced in several brain areas, including the SN and the
ventral tegmental area (VTA) (Purves et al., 2007). Dopamine biosynthesis in the body
begins with hydroxylation of the amino acid L-tyrosine to L-DOPA via the enzyme
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tyrosine hydroxylase and then by decarboxylation of L-DOPA by dopa decarboxylase
(Figure 3). In some neurons, DA is further processed into epinephrine and norepinephrine
by dopamine beta-hydroxylase (Purves et al., 2007). In neurons, DA is packaged after
synthesis into vesicles, which are then released into the synapse in response to a
presynaptic action potential. In most areas of the brain, including the striatum and BG,
DA is inactivated by reuptake via the dopamine transporter (DAT) (DziedzickaWasylewska, 2004), then is broken down by monoamine oxidase (MAOA and MAOB).
Dopamine neurons are mostly present in the VTA of the midbrain, the SNc and
the arcuate nucleus of the hypothalamus. This forms the neurotransmitter system,
composed of axon projections to large areas of the brain which are divided into four
major pathways: mesocortical, mesolimbic, nigrostriatal, and tuberoinfundibular
pathways (Hung et al., 1995). The mesocortical pathway connects the VTA to the frontal
lobe of the prefrontal cortex. Neurons with somas in the VTA project axons into the
prefrontal cortex. This pathway is important for normal cognitive functions in the
dorsolateral prefrontal cortex (part of the frontal lobe) and is involved in motivation,
emotion, and aspects of learning and memory. The mesolimbic pathway carries DA from
the VTA to the nucleus accumbens via the amygdala and hippocampus. The somas of the
projecting neurons are in the VTA. This is widely known as the “reward” pathway. The
tuberoinfundibular pathway runs from the hypothalamus to the pituitary gland. This
pathway controls the secretion of prolactin from the anterior pituitary gland. Of particular
importance is the nigrostriatal pathway, which runs from the SN to the neostriatum.
Somas in the SN project axons into the caudate nucleus and putamen. This pathway is
involved in the production of movement and belongs to a system called the basal ganglia
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motor loop. The degeneration of the nigrostriatal dopaminergic pathway consequently
results in a substantial striatal dopamine reduction, ultimately manifesting as symptoms
of PD (Dinis-Oliveria et al., 2006).
Etiology
The etiology behind almost 95% of the cases of Parkinson‟s disease is unknown
(Corti et al., 2005). The genetic inheritance in the origin of PD has been debated for more
than a century. A study by Tanner et al. (1999) initiated a large twin study of PD by using
the World War II twin‟s registry and the National Academy of Sciences registry. They
studied concordance rates in both monozygotic and dizygotic twin pairs and used 19,842
white males. These studies suggested that heredity plays an important role in cases with
age of onset <50 years and a less important role in older patients. Four genes have been
clearly linked to familial forms of PD. PARK 1 and PARK 5 lead to an autosomal
dominant form of PD with typical features such as early age of onset and rapid
progression of symptoms. PARK 1 encodes α-synuclein, leading to its abnormal
aggregation. PARK 2 and PARK 7 lead to autosomal recessive disorders, also with
atypical features, including juvenile forms of Parkinsonism (Kasper et al., 2005). PARK
2 encodes parkin, an E3 ubiquitin protein ligase. Mutations in parkin appear to be the
major cause of autosomal recessive PD. The identification of these and other mutations is
proving invaluable in refining the correlation between genotypes and phenotypes, in
generating animal models to study pathogenesis, and in identifying target pathways for
possible therapeutic intervention.
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Models to Study Parkinson’s disease
Numerous concerns exist in studies involving patients with Parkinson‟s disease.
Several studies have not succeeded in ruling out the possibility that the oxidative stress
indices found in PD brains are anything other than the nonspecific expression of dying
neurons. The postmortem tissue from end-stage PD is difficult to access due to ethical
issues, and when these tissues were obtained, the studied samples lacked dopaminergic
neurons. Another issue is that the majority of patients being used for postmortem studies
are patients that have used a battery of drugs, such as L-DOPA, which, like dopamine,
can readily auto-oxidize, giving rise to reactive oxygen species (ROS) (Parkinson‟s study
group, 2004). This however does not imply that chronic use of this drug will induce PD,
but does raise the concern that many observations from studies in humans may reflect
artifacts from the treatments received by PD patients before their death. For these
reasons, animal models of PD may be desirable in that they can provide controls against
such confounds as well as provide pre-clinical tests of therapeutic interventions. Since
PD does not spontaneously develop in animals, neurotoxic agents have had to be used to
induce the characteristic functional changes associated with PD. Some of the important
toxin-induced models are discussed in the following section of this paper.
MPTP Model
Several causative factors have been found to induce Parkinsonism similar to that
of idiopathic PD, including repeated head trauma, neuroleptic drugs, and manganese
toxicity (Adler, 1999). In particular, the toxicant MPTP (1-methyl-4-phenyl-1,2,3,6tetrahydropyridine), which was accidently discovered in the 1980s, resulted in the
development of Parkinsonism symptoms in a small group of drug addicts (Langston et
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al., 1983). These individuals injected themselves with the synthetic narcotic. The
postmortem analysis of these addicts revealed a selective loss of neurons and Lewy
body–like inclusions in the substantia nigra. These findings suggested that compounds
similar to MPTP in structure or biological activity might be the primary cause of sporadic
PD (Smeyne, 2005). By itself, MPTP is not toxic, but after reacting with monomine
oxidase and converting to its toxic metabolite MPP+, it is believed to cause cell death by
interfering with mitochondrial respiration (Costello et al., 2009) because it concentrates
in mitochondria and inhibits complex-I of the electron transport chain.
Several studies with MPTP have been conducted in nonhuman primates, rodents
and cats although a majority of studies have been performed on rodents such as mice
(Terzioglu, 2008). These studies showed that in various animals, MPTP induces damage
to the dopaminergic neurons in the nigrostriatal pathway identical to that seen in PD
(Bove et al., 2005). Various regimes and doses of MPTP were used to study PD
(Betarbet, 2002). Chronic administration of MPTP induces about 50–60% loss of
dopaminergic neurons in the substantia nigra. Susceptibility to this compound varies in
different species. In the MPTP mouse model of PD, time-course experiments suggest that
oxidative stress is an early event that may directly kill some of the dopaminergic neurons
(Beal, 2001). Systemic MPTP administration in mice induces PD-like symptoms,
including bradykinesia, rigidity and posture anomalies.
Pesticide and Herbicide Induced PD Models
Although the exact cause of PD remains unclear, numerous environmental risk
factors have been identified in the modulation of the disease onset and/or its progression
(De Monte, 2001, 2003; Di Monte et al., 2002). Several environmental agents are known
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to cause nigrostriatal damage and may contribute to PD, namely, aluminum (Altschuler,
1999); solvents such as methanol (Davis & Adair, 1999), and carbon monoxide (Klawans
et al., 1982). Gorell et al. (1998) assessed exposure to pesticides, farming, well-water use,
and rural living as risk factors for PD. They enrolled 144 patients with PD and 464
control subjects from metropolitan Detroit. They found a significant association of
occupational exposure to herbicides, insecticides and farming in general with PD. It has
been hypothesized that many chemicals used in agriculture are capable of selectively
targeting dopaminergic neurons, thereby accelerating the development of PD. Brown et
al. (2006) conducted a literature search of 10 major studies and found a consistent
association between exposure to pesticides and an increased risk of developing PD.
Particular classes of pesticides found to be associated with PD include herbicides, in
particular paraquat, and insecticides. Duration of exposure of more than 10 years was
found to be a risk factor in developing PD.
Paraquat Model of PD
Paraquat (PQ), or 1, 1‟- Dimethyl-4, 4‟-bipyridinium, is a herbicide commonly used in
many developing countries. This is a hydrophilic-charged molecule and therefore does
not diffuse across the blood–brain barrier (BBB) (Denis-Oliveira et al., 2006) but rather
through the neutral amino acid transporters. This toxicant is quick acting and kills plant
tissue on contact. Paraquat is an agent known to induce Parkinsonian symptoms in
humans and animals (Langston, 1983). Ingesting large dosages of paraquat causes liver,
lung, heart, and kidney failure within several days to several weeks and may cause death.
Moreover, studies have revealed a strong correlation between the amount of exposure to
non-lethal dosages of paraquat and Parkinson‟s disease (Liou et al., 1997; Morano et al.,
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1994). Liou et al. (1997) explored environmental risk factors for PD in Taiwan. They
recruited 120 patients with PD and 240 control participants in this study. All participants
underwent structured interviews and open-ended questionnaires to obtain histories of
their exposure to environmental factors, including place of residence, source of drinking
water and environmental and occupational exposures to various agricultural chemicals.
The authors suggested that there was an increased risk of PD associated with a history of
living in rural environments, farming, and the use of herbicides and pesticides,
specifically the agricultural use of paraquat (PQ). Moreover, the risk of PD was greater
among participants who had used paraquat than in those who had used other types of
herbicides and pesticides. It is important to note that the molecular structure of PQ is
similar to that of MPP+ (Figure 5). Recent mammalian and yeast-cell experiments
suggest that mitochondria actively take up PQ across their membranes where complex-I
reduce it to the paraquat radical action that subsequently produced mitochondriadamaging superoxide (Cocheme et al., 2008).
Studies of PQ toxicity have recently focused on its CNS effects. Unlike the
exposure to high levels of PQ that mainly produce pulmonary toxicity, chronic low levels
resulting from prolonged exposure to nonpneumotoxic doses may produce damage to the
basal ganglia. Toxic damage of the brain has been observed in patients who died from PQ
poisoning (Grant et al., 1980; Hughes, 1988). Autopsy findings in cases of acute PQ
poisoning showed cerebral damage with edema and neural death in the SN region.
However, in these studies, the possibility of whether the observed tissue changes
occurred either postmortem or as a consequence of anoxia due to respiratory dysfunction
could not be ruled out (Grant et al., 1980).
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Mechanism of Paraquat Toxicity
One mechanism by the cellular toxicity of PQ is essentially due to its redox cycle
which leads to the production of reactive oxygen species (ROS) (Castello et al., 2007).
Paraquat is reduced, mainly by NADPH-cytochrome P-450 reductase (Clejan &
Cederbaum, 1989). NADPH-cytochrome c reductase (Fernandez et al., 1995) and the
mitochondrial complex 1, also known as NADH:ubiquinone oxidoreductase (Fukushima
et al., 1993; Yamada & Fukushima, 1993) combine to form a PQ monocation free radical
(PQ+). It is generally accepted that PQ uses cellular diaphoresis, which are a class of
enzymes that transfer electrons from NAD (P) H to small molecules, such as PQ (Day et
al., 1999). The PQ monocation free radical is then rapidly reoxidized in the presence of
oxygen, generating the superoxide radical (O 2-) (Bush et al., 1998). This then sets off a
cascade of reactions leading to the generation of other ROS, mainly hydrogen peroxide
(H2O2), hydroxyl radical (HO), and the consequent adverse cellular effects. Indeed,
hydroxyl radicals (Bush et al., 1998) have been implicated in the initiation of membrane
damage by lipid peroxidation during the exposure to PQ in vitro (Busch et al., 1998) and
in vivo (Burk et al., 1980). These results were confirmed by McCarthy et al (2004) who
investigated the mechanism of cell death of differentiated in vitro human neuroblastoma
cells. They found that exposure to PQ produced cell death by causing oxidative stress and
subsequent mitochondrial dysfunction (McCarthy et al., 2004).
Paraquat has been found to selectively kill nigrostriatal dopaminergic neurons in
in-vivo animal models (Suntres, 2002). This study revealed that paraquat induced cell
death by causing oxidative stress. The details behind this interaction are still not clearly
understood. Somayajulu et al (2009) concluded that PQ administration into rat‟s causes
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the loss of DA neurons, specifically in the SNc. Results showed that with the doses of 10
mg/kg of PQ, damage was caused specifically to the DA neurons in the SNc without
producing any decrease in cells in other brain areas.
Paraquat-Maneb Model
Parkinson‟s disease has been reported to occur at higher rates among farmers and
in rural populations, leading to the hypothesis that agricultural pesticides, such as
rotenone, maneb (MB), as well as paraquat (PQ), might be causal agents. Additionally,
data from epidemiological studies point to an association between increased PD risk and
specific environments. Costello et al. (2008) investigated whether exposure to maneb
(fungicide) and paraquat (herbicide) alone and in combination increased the risk of
incidents of PD among residents of the Central Valley of California, an area well known
for its intensive agriculture and potential for pesticide exposure. They conducted
extensive interviews with 377 patients with PD and 755 eligible controls. The researchers
collected information on pesticide use as far back as 1974. The authors found that during
the period between 1974 and 1999 that agricultural application of both maneb and
paraquat within 500 meters of residences greatly increased the risk of developing PD.
Exposure to both pesticides during the earlier years studied also doubled the risk for older
cases. Association was strong for “younger-onset” patients (≤60 years), who would have
been children, teenagers, and/or young adults during the exposure period. Among those
who were exposed in the earlier years, risk was increased more than two times with
exposure to just one of the pesticides and more than four times with exposure to both
pesticides. Consistent with some theories regarding the progression of PD pathology
(Braak et al., 2003), these data suggest that the critical window of exposure to toxicants
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may be years before the onset of motor symptoms, which ultimately leads to a positive
diagnosis. Human data are insufficient to support this claim for any specific pesticide,
largely because of challenges in exposure assessment. Given the public health
implications concerning risk factors for the development of PD, the study of the
environmental factors involved in the etiology of PD has gained the renewed interest of
the scientific and medical community.
Experimental evidence of the neurotoxicity of such organic compounds has been
demonstrated in mice and rats. Studies have shown exposure to PQ alone or in
combination with MB results in loss of DA neurons in SNc and reduction in animals‟
general activity. Norris et al. (2007) found that exposure to a combination of the
fungicide maneb and the herbicide paraquat in mice led to increased substantia nigra
neuronal pathology. In that study, mutant human α-synuclein transgenic mice (M83) were
treated with the pesticides paraquat and maneb, either alone or in combination. The
researchers found that chronic treatment of M83 mice with both pesticides drastically
increased neuronal α-synuclein pathology throughout the CNS, including the
hippocampus, cerebellum, and sensory and auditory cortices. This study supports the
notion that environmental factors causing nitrative damage are closely linked to
mechanisms underlying the onset of Parkinson‟s- like neurodegeneration. Thiruchelvam
et al. (2003) tested whether exposing mice to different herbicides and/or pesticides would
produce Parkinsonism features. The authors used young adult mice of different age
groups (6 weeks, 5 months, or 18 months old). Subjects were exposed to the herbicide
paraquat, fungicide maneb, or paraquat and maneb. The results showed that paraquat and
maneb induced reductions in locomotor activity and motor coordination. The 18-month-
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old mice were most affected and exhibited failure to recover 24 hours posttreatment.
Progressive reductions in dopamine metabolites and dopamine turnover were exhibited,
and numbers of nigrostriatal dopaminergic neurons were reduced in all age groups
following exposure. Collectively, these data demonstrate enhanced sensitivity of the
ageing nigrostriatal dopamine pathway to these pesticides, particularly the paraquat+
maneb group, resulting in irreversible and progressive neurotoxicity. Cicchetti et al.
(2005) studied the effects of PQ and MB on dopaminergic (DA) neuron-glia, both in vitro
and in vivo cultures in young adult rats. In vitro, PQ led to a loss of DA compared to nonDA neurons and microglial activation in a dose-dependent manner. The addition of MB
had no further effect nor did it lead to microglial activation when used alone. In vivo, 2month-old rats were subjected to intraperitoneal injections (IP) of placebo, PQ alone, or
PQ in combination with MB, twice a week for 4 weeks, and then were sacrificed the day
following the last injection. The results showed a significant loss of nigral DA neurons in
both treatment groups. Microglial activation was seen in the substantia nigra of rats
subjected to PQ with or without MB. The authors further conducted behavioural-speed
and mobility testing, which measured the degree of hunchback position; speed testing
consisted of determining the speed at which animals conducted daily grooming, moving,
and exploring the cage; and mobility testing consisted of placing the animal on a trellis at
a 45-degree angle and assessing the degree of akinesia or bradykinesia. The behavioural
analyses showed a mixed pattern of motor impairments, which may have been due to
early effects of DA neuronal loss and/or systemic effects associated with MB exposure in
addition to PQ. This study concluded that exposure to PQ with or without MB induced
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neurodegeneration, which is thought to occur via an early inflammatory response in
young adult animals.
Molecular Mechanisms Contributing to PD
In Parkinson‟s disease, dopaminergic cells die due to a combination of factors
including excitotoxicity, mitochondrial dysfunction, and oxidative stress. However, the
exact mechanism of neurotoxicity is not yet fully known. A current available research in
this area will be discussed below.
Excitotoxicity
One of the mechanisms of neurodegeneration in several neurological diseases
(Dugan & Choi, 1999) is by the excitotoxicity induced by N-methyl-D-aspartate
(NMDA) receptor over activation. Excitotoxins like NMDA and kainic acid which bind
to these receptors as well as high levels of glutamate, can cause excitotoxicity by
allowing high levels of calcium (Ca2+) ions to enter the cell. Glutamate is an excitatory
neurotransmitter implicated in the development of the brain and synaptic plasticity
(Sandu et al., 2003). In vivo studies on the mechanisms of PQ-induced toxicity in the
striatum indicate that PQ stimulates glutamate efflux, initiating excitotoxicity mediated
by reactive nitrogen species (RNS). Increasing evidence shows that the excitotoxic injury
plays a critical role in the progressive degeneration of DA neurons in PD (Beal, 1998).
PQ induces continuous dopamine overflow and a consequent reduction of dopamine
synthesis (Dinis-Oliveira et al., 2006). However, no direct evidence has been found to
indicate excitotoxicity in PD.
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Mitochondrial Dysfunction in PD
Many lines of research point to possible mitochondrial dysfunction in PD.
Impaired electron transport hampers adenosine triphosphate production and leads to the
diversion of electrons from their normal electron transport recipients resulting in further
formation of damaging free radicals (Cassarino et al., 1999). The initial hypothesis that
mitochondrial complex-I deficiency may be involved in the etiology of PD came from the
findings that the mitochondrial complex-I inhibitor MPTP causes a clinical syndrome
indistinguishable from PD and selective dopaminergic cell loss in the substantia nigra
(SN) (Langston et al., 1983). Subsequently, complex-I activity was assessed and found to
be significantly reduced in platelet mitochondria in patients with PD compared with
controls (Hass et al., 1993). Complex-I activity was also reduced in the SN region but not
in other regions of the brain (Schapira et al., 1990 a, b).
Several studies suggest that mitochondrial complex-I of the electron transport
chain (ETC) is responsible for reducing PQ into its radical, which inhibits complex-I
activity, and finally leading to mitochondrial dysfunction (Dinis-Oliveira et al., 2006).
Castello et al. (2007) investigated the implications of the mitochondria on exposure to
PQ. Their results suggested that at least in the rat brain, mitochondria are a principal site
for PQ2+H2O2 production and that this production requires the presence of respiratory
substrates. This study found complex-III of the mitochondrial ETC as the main site for
reactive oxygen species (ROS) production.
Oxidative Stress in PD
Oxidative stress has been hypothesized to be one of the central mechanisms
linked to both the initiation and the progression of PD. Oxidative stress refers to the
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undue oxidation of biomolecules leading to cellular damage caused by ROS. The brain
depends mainly on energy produced from the mitochondria and almost 95% of the
molecular oxygen that is inhaled is metabolized by the mitochondrial electron transport
chain. ROS may be formed during a number of cellular processes including
mitochondrial oxidative respiration and dopamine metabolism. Mitochondria are the
major source of ROS at the cellular level. Free radicals produce oxidative damage by
reacting with DNA, lipids and proteins (Betarbet et al., 2002).Various neurodegenerative
disorders and syndromes are associated with oxidative stress (Behl, 2002). At several
sites along the ETC are sites of “electron leak” (Arnaiz et al., 1999). These electrons may
combine with molecular oxygen and thereby form ROS, such as superoxide (O 2-) and
hydrogen peroxide (H2O 2) (Halliwell, 1987). The mitochondrial electron transport chain
produces ROS at complex-I and complex-III. It is suggested that increase in ROS is a
consequence of the impairment of the mitochondrial respiratory chain (Fluery et al.,
2002). H2O2 is not a free radical but can penetrate cell membranes, making it very toxic
to the cell (Rhee, 1999). Several studies emphasize the contribution of oxidative stress in
nigral cell death in PD. This has been demonstrated by postmortem studies in patients
with PD as well as toxin-induced PD models (Dickson, 2007; Jenner, 2003). The
evidence of increased oxidative damage includes increased levels of lipid peroxidation,
DNA damage, and protein oxidation observed in the SN region in patients with PD
(Zhang et al., 1999). Furthermore, oxidative stress is linked to other cellular processes
such as cell death, excitotoxicity and mitochondrial dysfunction; therefore it is not easy to
establish whether oxidative stress is the primary initiating agent or a product of these
events (Jenner, 2003).
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Advances in Therapeutic Approaches to PD
Much progress has been made in the treatment of PD as a result of advances in
experimental therapeutics. Many promising therapies are available for PD, and currently
symptomatic treatments are available focusing on treating the symptoms of the disease.
These options include dopamine replacement strategies, nondopaminergic therapies,
surgical approaches and very few neuroprotective therapies that are under research.
Pharmacological treatment has two main objectives: (1) to increase the activity of
remaining dopamine synapses and; (2) to suppress the activity in structures that show
heightened activity in the absence of adequate dopamine action. Levodopa (L-DOPA),
which is directed toward comfort and support, is the most potent drug for controlling PD
symptoms. L-DOPA is converted into dopamine in the brain, enhancing effective
dopamine transmission. Long-term (> 5 years) use of this drug is associated with
significant complications, such as a “wearing off” effect, L-DOPA-induced dyskinesias,
and other motor complications, such as fluctuations and dyskinesias and other
complications (Stern, 2004; Jankovic, 2005). Further, L-DOPA is shown to be toxic to
dopamine neurons and can produce harmful ROS by oxidative metabolism of dopamine,
which in turn may hasten the rate of progression of the disease (Olanow, 2008).
Another extreme form of therapy available is surgery which involves destruction
of certain parts of the brain (thalamus, the globus pallidus, and the subthalamic nucleus)
or insertion of electrodes into these areas for electrical stimulation is available for
patients with PD (Savitt, 2006). This option is usually given to patients with moderate to
severe PD and/or to patients who are not able to tolerate medications available for this
disease.
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Neuroprotective approaches have shown to be very promising in slowing the
progression of the disease and limit the extent of neuronal cell loss in PD. The use of
neurotrophic factors such as neurturin (NTN) (Kordower et al., 2006) and the glial cell
line–derived neurotrophic factor (GDNF) (Gash et al., 1998), have been reported to
enhance the survival of midbrain dopaminergic neurons. Bioenergetic compounds such as
creatine, riboflavin, and CoQ10 are also shown to be neuroprotective agents for PD in
both animal models and humans (Beal, 2003b). These studies are still under research and
have not shown any efficacy in slowing down neurodegerative disorders such as PD.
CoQ10 as a neuroprotective agent.
The etiology of several neurodegenerative disorders is thought to involve
impaired mitochondrial function and oxidative stress, which are evident from studies with
animal models, studies of mitochondria from patients, and analysis of genetic defects.
Coenzyme Q10 (also known as CoQ10; 2, 3, dimethoxy-5 methyl-6-decaprenyl
benzoquinone; ubiquinone) is a naturally occurring compound that participates in
electron transfer in the mitochondrial oxidative respiratory chain for complexes-I and
complexes-II of the electron transport chain. CoQ10 can accept one electron and be
converted to an intermediate semi-ubiquinone, which can then accept one electron to be
converted to its reduced form called ubiquinol (Figure 4). When reduced to ubiquinol, it
is a powerful antioxidant that prevents oxidative damage from free radicals, including
oxidation of lipids within the mitochondrial membranes, and protects DNA and proteins
from free radicals (Ernster, 1995; Geromel et al., 2002; Matthews et al., 1998). Oxidative
stress burden in the midbrain is usually high under normal conditions due to generation of
reactive metabolites of DA and is further elevated during aging, especially in patients
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with PD (Brown et al., 2006; Ernster, 1995). Schults et al. (1997) measured levels of
CoQ10 in mitochondria from subjects who have PD. CoQ10 levels were found to be
significantly lower in patients with PD compared to age-matched controls. These findings
support the idea that increasing CoQ10 levels could be of therapeutic benefit.
Clinical trials, including an open-label phase trial of CoQ 10 in patients with PD,
have found good CoQ10 absorption and tolerability (Beal, 2003b). A recent study by
Storch et al. (2007) conducted a randomized clinical trial of a 300 mg dose of CoQ 10 in
131 patients with PD who did not have changes in motor functions and were on stable
treatment for their condition. Those assigned to the treatment group took 100 mg of
CoQ10 three times daily for three months, followed by a two-month “washout” period.
The researchers assessed Parkinson‟s disease symptoms before treatment began, each
month during treatment, and again after the washout period. The compound was well
tolerated and the occurrences of adverse effects like viral infection, diarrhea and hearing
loss were equal between the two groups. This study demonstrated an increase in blood
levels of CoQ10 in the treatment group, from an average of 0.99 mg/L to an average of
4.46 mg/L after three months. However, this study failed to show improvement of
Parkinson‟s disease symptoms as it did not meet its primary or secondary end points,
which were changes on scales that measured Parkinson‟s disease symptoms and their
effects on physical and mental functioning. The pharmaceutical applications seem to
suffer from the lack of solubility and low bioviability, both of which are needed to
achieve therapeutic effects.
Although CoQ10 is classified as a lipophilic compound, its degree of solubility in
lipids is limited, and it is practically insoluble in aqueous solutions. Recently, a water-
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soluble formulation of CoQ10 (WS- CoQ10) was prepared by Drs. M. Sikorska and H.
Browhy-Borowski of the national Research Council of Canada using a patented protocol.
In 2006, Bhagava and Chopra reviewed available research data on the absorption,
metabolism, and pharmacokinetics of CoQ10 . They found that in many cases, the soluble
form of CoQ10 shows enhanced bioviability in its uptake in cells; moreover, its beneficial
effects on cardiovascular and neurodegenerative diseases, and its antioxidant properties
were demonstrated (Bhagava & Chopra, 2006).
Human neuroblastoma cells pre-treated with WS- CoQ10 have been shown to
prevent against PQ-induced neuronal cell death (McCarthy et al., 2004). Sandu et al.
(2003) exposed neurons to 10 μg/ml of WS- CoQ10 for three days. The investigators
found that this treatment resulted in an increase of cellular ATP levels, with an increase
of CoQ10 in cellular mitochondria membranes and cell membranes. In addition, they
found that WS- CoQ10 can prevent against neuronal cell death caused by glutamate
excitotoxicity (Sandu et al., 2003). Somayajulu-Nitu (2009) reported that prophylactic
application of a water-soluble formulation of CoQ10 could effectively offset the effects of
the environmental neurotoxin paraquat. They used a model of paraquat-induced
dopaminergic neurodegeneration in adult rats that received three weekly intraperitoneal
injections of the herbicide paraquat. They found increased levels of oxidative stress
markers and a loss of approximately 65% of dopamine neurons in the substantia nigra
region. In addition, the researchers found that rats receiving a water-soluble formulation
of CoQ10 in their drinking water prior to and during the paraquat treatment neither
developed neurodegeneration nor reduced performance on their behavioural assessment
(rotorod) than the control paraquat-untreated rats. Given the research discussed on the
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potential benefits of WS- CoQ10 and protection against neurodegeneration, the current
study is aimed at further evaluating the efficacy of WS- CoQ10 in rats induced with
Parkinson‟s disease.
Serial Reaction Time
Sequential learning entails learning to organize sequences of behaviour so as to
anticipate events occurring in a consistent sequential order. Stewart Hulse and colleagues
initially studied such learning in rats by systematically varying amount of food at the end
of a long runway over trials and examining rats‟ changes in running speeds over these
trials as food quantities consistently changed. Results from a series of studies suggested
that rats learn to anticipate patterned sequences of events or “serial patterns”. Hulse and
Dorsky (1977) presented rats with a simple monotonic pattern sequence of 14-7-3-1-0
food pellets in Experiment 1 which they considered promoted a single “less than” rule to
describe the relationships of all successive pairs of quantities. Other rats received
nonmonotonic pattern sequence 14-1-3-7-0 food pellets which would generate a more
complex combinations of “less than,” “greater than”, and “equal” rules to describe the
patterns. Rats learned to anticipate (run more slowly down the non-rewarded runway)
more easily with the simple monotonic than nonmonotonic pattern. In Experiment 2,
some rats experienced a weaker monotonic pattern 14-5-5-1-0 pellets that was
intermediate between the monotonic and nonmonotonic pattern sequences given to other
rats. These animals learned to adjust their running speeds less easily to weaker than
stronger monotonic pattern. Hulse and Dorsky (1977) concluded that rats are sensitive to
pattern structure and can learn the rules that described the structure. In a later experiment,
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they also showed that rats could generalize a rule from one set of patterns to a different
pattern (Hulse and Dorsky, 1979).
Capaldi and Molina (1979) challenged the theory that rats learned rules by
maintaining that patterned performance could be accounted by rats acquiring simple
stimulus associations and generalizations in pattern learning. According to this notion,
food quantities earlier in a sequence serve as cues for the later food quantities. Fountain
and his research team provided clearer evidence that rats learn a simultaneous rule from
sequential patterns rather than simple successive associations. For example, Fountain et
al., (2006) trained rats in an octagonal operant chamber equipped with a retractable lever
mounted on each wall designated 1-8 in a clockwise fashion. In their typical procedure,
all levers are presented at the beginning of each trial allowing the rat to press any of the 8
levers. If the correct lever is chosen, the rat receives brain-stimulation reward (BSR) via
implanted hypothalamic electrodes. If an incorrect lever is chosen, all levers except the
correct lever are withdrawn from the box and the rat must make a correct choice to
receive BSR before continuing to the next trial. Rats were required to learn two patterns
of successive lever choices, a “perfect” pattern (123-234-345-456-567-678-781-812) and
one containing a “violation” pattern (123-234-345-456-567-678-781-818). They were both
identical, but the violation pattern contained a single element at the end of the pattern that
violated the simple structure. Rats were given 24-element response patterns which can be
described as composed of either 3-element “chunks” that share a common base “rule”
within chunks, usually “+1” rule. In the violation pattern, there is an exception to the rule
for the last element. Now, the rule is “+2”, which would be a correct response. The
authors found that rats learn to use combinations of multiple pattern elements to respond
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properly in a trial and anticipate the violated element. We note that this task requires
considerable training over several sessions before rats show any reasonable accuracy in
lever choices. Although Fountain has successfully used this as a behavioural assessment
to examine neurological function of NMDA receptors, a specific type of glutamate
receptor which plays a critical role in hippocampal learning (Fountain et al. 2000) we do
not consider this preparation logistically suitable for our goals. Rather, in reviewing the
literature on serial pattern learning we discovered a far easier-to-learn serial reaction time
task initially given to humans and later shown to be similarly easy to acquire by animals.
The main reasons behind studying sequential learning by using the serial reaction
time (SRT) task are: (1) sequencing of information and actions is a fundamental human
ability; (2) sequence learning is an easily studied example of skill acquisition (i.e.,
reaction time and error rates are reliable measures for determining improvement in
sequential learning; and (3) sequence learning may be a complex form of implicit
learning.
Nissen and Bullemer (1987) developed a simple paradigm that now forms the
basis of much of the research on sequence learning. In this task, human participants sit in
front of the computer screen and are shown an asterisk which appears in one of four
locations across the monitor. Participants are instructed to react to the presentation of the
stimulus by pressing one of the four keys positioned below the stimulus. A correct
response makes the stimulus disappear and another asterisk later appears in one of the
other three positions. Location of response follows a pattern whereby the stimuli follow a
10-trial sequence which is then repeated. The beginning and end of the sequence are not
marked. Each participant typically receives 10 repetitions of the sequence (100 trials),
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which makes up a block, and typically a total of four blocks are presented. At the end of
the fourth block, a fifth block is presented in which the position of the stimuli is
randomly determined. The dependent variable is reaction time to respond to each
stimulus (RT), and learning of the sequence is inferred from a reduction in RT over the
four learning blocks followed by an increase in RT on the fifth block containing a
random sequence. The RT provides a measure of participants‟ growing expertise in
performing not only the sequence but also in learning the visuomotor association or
mapping between the position of the visual cue and the required response. This difference
in RT between pattern and random trials indicates the extent of learning to fixed pattern.
Despite the performance difference, some participants are unable to express declarative
knowledge of the nature of the fixed and random sequences. Consequently, their learning
is considered to be implicit.
Nissen and Bullemer (1987) also gave the SRT task to patients with amnesia.
They found that amnesic patients show these learning patterns despite their lack of
awareness of the sequence. Willingham (1989) showed that reaction times can be
improved with repeated sequences even if the subject was not aware of this learning. This
study used an SRT task similar to that used by Nissen and Bullemer (1987) in which they
investigated procedural learning in normal subjects. Locurto et al. (2010) examined the
acquisition of sequence information by cotton-top tamarins (Saguinus oedipus). The
authors wanted to know what subjects learn in the absence of explicit reinforcement for
correct responses. Two experiments were conducted using an implicit chaining
procedure. Visual stimuli were presented serially on a touch screen. Subjects were
required to touch one stimulus to advance to the next stimulus. These stimuli were
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presented in a fixed pattern, but learning the pattern was not necessary for reinforcement.
In experiment 1, five different visual stimuli were presented in the same order on each
trial, each occurring at any one of the six positions. In experiment 2, the same visual
element was presented serially in the same five locations on each trial, which allowed a
behavioural pattern to be correlated with the visual pattern. In addition, two new tests, a
Wild-Card test and a Running-Start test were used to assess what was learned in this
procedure. Results indicated that tamarins acquired more information about the
sequential nature of the stimuli than by the rules of reinforcement. The authors concluded
that even without explicit reinforcement for correct responding, tamarins can learn
several features of patterned information, including the sequence position of elements in
a series and the perceptual characteristics of those elements.
Domenger and Schwarting (2007) developed a rat version of the human SRT task.
They trained rats to nose-poke one of the four locations (illuminated nose-poke hole) to
obtain a reward under sequential conditions. The authors investigated the effects of
violating a single stimulus position in the series to determine whether the rats still
attended to the actual stimulus order when confronted with sequence violations. Random
conditions showed slower reaction times and lower response accuracy compared to fixed
sequential conditions. In-depth analysis of the incorrect responses showed that most rats
directed their errors to the position where the stimulus would have normally appeared.
In the standard serial reaction time task, individuals might learn either the
perceptual or motor sequence separately or in some combination. Although the SRT task
is often viewed as a motor learning task, it is not clear that learning is taking place solely
in the motor domain. The motor theory of implicit sequence learning focuses on
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responding to each stimulus. This model suggests that individuals learn a sequence of
manual response movements and this learning is tied to motor-related output (Goschke et
al., 2001). Goschke et al. (2001) modified the common SRT tasks as follows. In their
task, four letters (A, B, C, and D) were presented horizontally in discrete locations and
each letter corresponded to one of the four response keys on the keyboard. In contrast to
previous SRT tasks, where each stimulus would appear one at a time, all letters were
presented visually on every trial. Following the visual stimuli, one of the four letters was
spoken and heard through headphones. Participants were instructed to respond by
pressing the key directly below the letter they heard. Unlike previous SRT tasks, location
of stimuli on the computer screen changed with each trial. The change of location altered
the associated motor response from one trial to the next. Results showed that normal,
healthy participants demonstrated implicit based sequence learning in the absence of
spatio-motor sequencing. The serial pattern could be learned as a sequence of motor
responses with participants learning the correct sequence of response buttons (Robertson,
2007). Alternatively, the serial pattern could be learned perceptually, that is, as a
sequence of visual cue positions. Over time, participants would learn to predict the
position of each visual cue and so would quickly respond to the appearance of the visual
cue. Dennis et al. (2006) investigated people‟s ability to learn perceptual sequences in the
absence of motor sequencing, using an SRT task similar to the one used in the Goschke et
al. (2001) study. Dennis et al.‟s (2006) study concluded that both younger and older
adults can learn simple first- and second-order sequences in the absence of a spatiomotor
sequence (i.e., sequence learning can be supported by purely perceptual learning, but this
only occurs when the SRT task has been modified to remove the motor sequence). With
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no motor sequence, individuals are forced to learn perceptually. In contrast, when both
perceptual and motor sequences are available, then learning occurs in both domains.
Work done by Willingham et al. (1999) tested the hypothesis that implicit sequence
learning could be supported by purely perceptual information. They concluded that
sequence learning is not purely perceptual learning. Thus, sequential learning can have
both motor and perceptual learning.
While performing the SRT task, individuals acquire the skill of producing the
sequence, which is shown by the reduction of reaction time over trials for fixed-pattern
sequences. In these cases, individuals can also acquire an ability to declaratively describe
the sequence. After performing the SRT task, an individual might be able to verbally
describe some or all of the sequences contained within the task. Thus, the SRT task is not
exclusively a motor learning task; it includes an important declarative component and is
demonstrated by the ability to verbally describe some or all of the sequences within the
SRT task. Brown et al. (2007) disrupted sequence learning in individuals by having
participants learn a word list immediately after sequence learning. After 12 hours of
being tested with SRT and learning a word list, the participants were retested on the SRT
and word list and then were administered a free recall test of the sequence. The results
showed that learning a word list immediately after acquiring the SRT disrupted the
declarative representation of the sequence, thereby reducing participants‟ ability to
describe the sequence.
SRT and Brain Processes
Motor skill learning is supported by a circuit that includes motor cortical and
subcortical areas such as the striatum and cerebellum (Robertson, 2007). Keele et al.
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(2004) analyzed several studies and theories behind the brain processes of the SRT task
and found that a similar pattern of areas are engaged during learning in the SRT task. The
prefrontal cortex, striatum and cerebellum all make contributions during this task. Several
studies report that the medial temporal lobes (MTL) are involved in SRT only for the
acquisition of high-order sequence learning but not low-order sequence learning. In
second-order sequences, predicting the next event requires knowing the two immediately
preceding events (Curran et al., 2007; Schendan et al., 2003). Procedural memory has
been associated with subcortical structures of the basal ganglia (Eichenbaum et al., 2001).
Further, Positron Emission Tomography (PET) studies of SRT learning have shown that
activation changes within the basal ganglia are associated with learning and the parietal
and temporal cortex (Grafton et al., 1995; Haseltine et al., 1997). Under implicit
conditions, activation of areas is commonly associated with motor control, including
motor cortex and subcortical areas in the basal ganglia (Curran, 1998).
Over the past 20 years many studies using SRT have been performed on primates,
healthy human subjects, and patients with brain damage (i.e., Huntington‟s disease [HD],
Alzheimer‟s disease [AD], and Parkinson‟s disease [PD]). These studies attempted to
detail possible brain mechanisms involved in sequential learning. Knopman and Nissen
(1991) studied procedural learning in patients with HD using a four-choice SRT task.
Participants were given a total of five blocks; the first four blocks were of a fixed pattern
of stimuli and the last block consisted of random pattern of stimuli. Results showed that
although there was a reduction in reaction time in the fixed sequences compared to the
random sequences, there was an increased reaction time compared to the healthy controls
for reaction time for both types of sequences. More importantly, the individual analysis
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of patients with HD showed that these patients failed to exhibit a sequence-specific
learning. Knopman (1991) later studied procedural learning in patients with Alzheimer‟s
disease using the same SRT task. Results showed that both patients with AD and normal
controls had the same reaction times across the sessions; however, all patients with AD
lacked the awareness of these sequences.
A number of studies have examined the performance of patients with Parkinson‟s
disease using the SRT task. Interest in this group arises from evidence that suggests that
the basal ganglia, which are compromised in this group of patients, may play a critical
role in procedural learning. Ferraro et al. (1993) examined implicit memory performance
using the SRT task in four groups of subjects: (1) healthy and aged individuals; (2) nondemented individuals with Parkinson‟s disease; (3) individuals with mild Alzheimer‟s
disease; and (4) individuals with mild cognitive impairment. The SRT task involved four
blocks of a repeated pattern of a 10-item key press sequence that tapped general skill
development along with a fifth block of a non-repeated sequence that emphasized the
impact of switching from a learned set of associations. The researchers found that
patients with non-demented PD demonstrated less sequence learning than controls in the
SRT task. Siegert et al. (2006) conducted a meta-analysis of sequential learning in
patients with PD and found impaired implicit learning in this population. However, it was
pointed out that these studies were not methodologically consistent. For example, several
studies lacked the inclusion of random blocks after sequential conditions and did not
control for the severity of the disease when recruiting participants. Despite these
problems, researchers in animal behavior and cognition have begun to use SRT tasks to
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examine effects of interference with dopamine production on such sequence learning and
performance in rats.
Eckart et al (2010) investigated the effects of bilateral neostriatal dopamine
lesions induced by 6-hydroxydopamine on sequential learning in rats. This study used the
operant rat version of the human four-choice SRT. The rats were tested on an interference
test. That is, the rats were presented with a stimulus that switched between a sequential
and a pseudo-random order every 5 minutes and a violation test in which one sequence
item was skipped. The lesion group received bilateral intracranial injections of 6OHDA.HCl into the striatum, with two injection sites per hemisphere before the start of
training, which resulted in subtotal dopamine depletions (35–56%) in the medial
neostriatum. This study also included operated and non-operated control groups. Results
from this study revealed that the lesioned group showed less response accuracy and
slower RT than the control groups. During the alternating phases of sequential and
random stimulus presentations, RT and accuracy of the control group were better during
sequential sequences when compared to random sequences. In the lesion group, only a
moderate advantage in accuracy was observed. In the violation test, the control group
showed an expected increase in RT on the violated positions. In the lesion group, RT did
not increase, which suggested less automation of sequential behaviour. This study
concluded that neostriatal dopamine plays an important role in acquiring or maintaining
sequential behaviour. The current thesis further examines the effects of destruction of
dopaminergic brain area on rats‟ SRT performance and on the potential to use of this task
as a diagnostic tool in assessing the neuro-protective effects of post-insult treatment with
a water soluable formaulation of CoQ10. The neuro-protected group should show no
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change in their RT or errors compared to the placebo group in their post-injection
behavioural assessments. The non-protected group should show increased RT and more
errors compared to the protected group and the placebo group.
Objectives
1. To develop a rat SRT preparation for investigating performance as a function of
sequence structure
2. To study the neuroprotective effects of water-soluble coenzyme Q10 (WS- CoQ10)

by evaluating the behavioural effects on the SRT using the paraquat-induced
sporadic Parkinson‟s disease model in Long-Evans hooded rats
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CHAPTER III
DESIGN AND METHODOLOGY
Materials
Experimental animals.
Twenty-five male Long-Evans hooded rats, purchased from Charles River
Breeding Farms, St. Constant, Quebec, were used in this study. Only twenty-four animals
were used for data analysis, one animal was dropped out of the study. When the rats
arrived at the facility, they were randomly split into two groups: one that would receive
injections of PQ (10 mg/kg) and the other that would receive injections of saline. These
two groups were then further divided into groups based on their water regimen: whether
they received WS- CoQ10 (50 µg/mL) in their drinking water (H2O) (Figure 5). On
average, the rate of water consumption for a rat is 10 ml per 100 g of body weight each
day. An average rat weighing 500 g would therefore consume 5 mg of either WS- CoQ10
or H2O. The rats were approximately 2 months old and weighed an average of over 300 g
at the beginning of the study. There were three to four rats per group cage. After each
experimental session, they were fed 20–25 g of food (Purina Rodent Chow) and its
specific liquid for 2 hours in individual holding cages only before being returned to their
large-group holding cage in the colony room. This regimen was necessary for long-term
maintenance of the rats‟ weight and prevented dominance hierarchies based on the degree
of neurodegeneration between the paraquat-injected animals and the saline-injected
animals. This regimen prevented the possibility that the saline-injected rats and/or the
neuroprotected rats might dominate other rats and gain access to liquid and food. The
rats‟ specific liquid was freely available in group and holding cages. This regimen
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maintained rats at approximately 90% of their free-feeding weights over the course of the
experimental period. Towards the end of the study, the rats weighed between 400 g and
500 g. Rats in either their individual cages or group cages had access to drinking
solutions (regular water or with water supplemented with WS- CoQ10). Bottles that
contained WS- CoQ10 were wrapped in aluminum foil to prevent degradation of the
compound and were refilled every day. Illumination in the colony room was maintained
on a reversed 12:12 hour dark/light cycle, and experimental sessions always began within
3 hours before the beginning of the dark cycle to ensure that these nocturnal animals were
awake and active during their SRT sessions. The colony room was maintained at
temperatures of 20°C–24°C. All animal care, procedures, and treatments were approved
by the University of Windsor‟s Animal Care Committee and were in accordance with the
Canadian Council for Animal Care Guidelines.
Water-soluble formulation of CoQ10 (WS- CoQ10).
Water soluble CoQ10 (WS- CoQ10) was obtained from the National Research
Council. The WS- CoQ10 was produced through a patented protocol (U.S. patent #6 045
826), which contained a 2:1 (w/w) ratio of oxidized and reduced forms of CoQ 10,
respectively. CoQ10 was contained within a water-soluble “cage” composed of
polyethylene glycol and α-tocopherol (vitamin E). Stock solutions of WS- CoQ10 (50 mg
of CoQ10 and 150 mg of PTS per mL in phosphate buffered saline) were diluted with
regular drinking water to a final concentration of 50 µg WS- CoQ10 per mL.
SRT apparatus
Three 48.3×22.9×27.9 cm standard operant chambers (Figure 5) were placed in
separate sound-attenuated chambers. In each chamber, five light-equipped nose-poke
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holes, each covered by a translucent plastic disk and were arranged horizontally. The
pellet receptacle was placed on the opposite side of the nose-poke holes, and a house light
and speaker were attached directly above. The pellet receptacle was attached to a
dispenser, which delivered sugar pellets. Infrared devices detected entries into the nosepoke holes and the food receptacle. The whole system was controlled and monitored by a
program created by the Tech-Support Centre, University of Windsor with LabVIEW
software.
Behavioural Assessment
Phase 1- Shaping
The rats were trained on the SRT apparatus and were required to respond to a
discriminative visual stimulus which in this case, was the illumination of middle of five
nose-poke translucent keys. Rats were required to poke the key before it was darkened to
receive a food pellet before being trained on a sequence of lit keys before each
reinforcement. Following this initial training, rats were trained to respond to a series of
illuminated holes before being reinforced; the final level in this experiment was on a
fixed-ratio schedule of 5 (FR5). During the first 3 weeks of shaping, the rats were trained
daily for 10–30 min per day. Initially, one hole was illuminated for 20,000 ms and poking
at this hole was reinforced on a continuous reinforcement schedule (FR1). For each
illuminated hole that the rat pokes, the rat would get reinforcement. When the rat learned
to respond at this signal, it was shaped to respond to an FR2, FR3, and finally an FR5
schedule. A typical trial (FR5) was initiated by a house light which lasted for 5,000 ms.
Immediately after the house light went off, one of five nose-poke keys was illuminated
for 20,000 ms. The subject terminated the key by poking the illuminated key. The inter-
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signal interval was 0 ms, at which point the next key was lit for 20,000 ms. After all five
keys had been poked, the tone (75 dB noise) would turn on for 1000 ms, indicating that
the reinforcement was ready. The subject would then poke the food receptacle with its
nose to obtain a reward. The next trial was initiated after the subject obtained
reinforcement.
Phase 2- Pre-injection
Subjects were then tested using the ABA sequences. The sequences were of two
types: fixed (A) or random (B). In fixed sequences, one of five nose-poke locations
(Figure 6) was presented in a fixed order with no repetition (e.g. 31452, 31452 and
31452). In the random condition, the five nose-poke locations were presented randomly
with no repetition among the sequences (e.g.13452, 41325, 51234 and 12354). The
random patterns for each subject were computer generated. Subjects were trained one
session per day for 15 days. Each session consisted of 300 nose pokes with every fifth
correct nose poke reinforced. Of the 300 correct nose pokes, the first 100 were of fixed
sequence (A), followed by a random sequence for 100 nose pokes (B), and finishing off
with the same fixed sequence of 100 nose pokes (A). For these sequences, the house light
was on for 5,000 ms and the inter-signal-interval was 1,000 ms. These parameters were
chosen in these experiments because they were used in previous studies using the SRT.
The signal light was illuminated for 3,000 ms. The rats‟ latency, or reaction time, to press
a lit key was measured in milliseconds. If the rats failed to poke a lit key, the signal
would turn off and reappear after 1,500 ms. This sequence continued until the animal
poked the lit key. If the animal poked an unlit key while the other key was lit, the lit key
would be terminated and would turn on after a 1,500 ms delay. Poking an unlit key was
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labeled an incorrect choice while failure to respond was designated an omission..During
this phase, all rats received H2 O (tap water) in their individual holding and group home
cages.
Phase 3- Post-Injection
Injection regimes.
Figures 7 and 8 describe the group allocation and the time line for this phase
respectively. Previous studies, such as the one conducted by Somayajulu et al. (2009),
conducted several experiments to induce selective damage to DA neurons in rats‟ SNc.
For the first experiment, rats were given three intraperitoneal injections of PQ (10 mg/kg)
to induce selective damage to DA in the SN in mice, used similar protocol to
(McCormack et al., 2002). In the second experiment, rats were given eight intraperitoneal
injections of a combination of PQ (10 mg/kg) and the fungicide MB (30 mg/kg), same
regimens as per (Thiruchelvam et al., 2000a; Thiruchelvam et al., 2000b). These
treatment regimens were fatal to a large number of rats during injections and were
discontinued. Since the PQ and MB regime was not tolerated by the rats, Somayajulu
(2009) decided to use eight injections of 10 mg/kg PQ alone twice a week for four weeks.
This regime was toxic to the rats, and the experiment was discontinued. In the final
experiment, rats were given five injections of PQ to yield greater neuronal loss than in the
three-injection regime. In all of the above experiments, rats were divided into six groups.
These groups included saline water, saline placebo, saline WS- CoQ10 PQ-water, PQplacebo, and PQ-WS- CoQ10. The rats were fed drinking water supplemented with their
treatments after 2 weeks of arrival to the facility. In her pilot research, Somayajulu found
greater neuronal loss when the rats were injected five times compared to three times.
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Since the five-injection regime yielded greater neuronal loss, the current experiment used
this schedule.
In the current study, subjects were randomly divided into three groups (Figure 7),
with the following number of subjects in each: (i) paraquat and WS- CoQ10 group (n=12),
(ii) paraquat and H2O group (n=6), and (iii) saline and H2O group (n=7). This experiment
was designed to study only the therapeutic effect of WS- CoQ 10. The number of subjects
for each group was determined by the research team from the biochemistry department at
the University of Windsor that was also responsible for injection and post-mortem
protocols (Facecchia et al., 2011, in progress). After the collection of 15 days of baseline
data (pre-injection phase), the rats were injected with either 10 mg/kg intraperitoneal
paraquat injections or saline injections every five days for a total of five injections.
During the time of injections, subjects were fed tap water (H 2O), and were not run on the
SRT task. Immediately after their fifth injection, the 12 rats that received paraquat were
fed WS- CoQ10 to investigate its therapeutic effects in halting any post-injection PQinduced neurodegeneration. The remaining rats were fed with H 2O. After three days of
the last injection, the subjects were run through the SRT protocol for another 15 days.
Each subject was given the same sequence as previously indicated in the preinjection
phase. After conducting the postinjection behavioural studies, the rats were dissected, and
tissues were collected for histochemical analyses as part of Katie Facecchia‟s master‟s
thesis at the University of Windsor. We note that one rat in the PQ+WS-CoQ10 group
failed to acquire the SRT task during baseline training was not further tested on this task
during the remainder of the study. Thus the PQ+WS-CoQ10 group was reduced to 11 rats
so that SRT performance was assessed and analyzed on 24 animals.
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Statistical Analysis
Individual response types and reaction times were analyzed. The following
response types were used: (a) correct nose-pokes (responses to illuminated holes), (b)
incorrect nose-pokes (responses to non-illuminated holes), and (c) omissions (no
response during a lit key). The reaction time (ms) elapsed between the onset of the
stimulus and the nose-poke of each correct response was normalized to reduce variation.
This was done by dividing 1,000 by the reaction time for each rat to each signal. These
reciprocal RT values were then averaged over blocks of three days for each signal at each
block of fixed and random sequences and then reconverted into normalized mean RT
scores by dividing the mean reciprocal RT by 1000 of each rat. The various two-way and
three-way Analyses of Variance were conducted on rats‟ normalized mean RTs as
described in the results section. Each rat‟s total number of omissions and total number of
incorrect choices over all pre-and post-injection sessions and over each block of three
sessions within each pre- and post-injection phase for fixed and random sequences were
also analyzed by two- and three-way ANOVAs respectively. All statistical analyses were
calculated with IBM SPSS (version 19) software. For this and all other analyses a
significance level used was p < .05.
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CHAPTER IV
ANALYSIS OF RESULTS
Reaction Time
The means of each rat‟s normalized reaction time (RT) for each session‟s signal
position in from each within-session block of sequences (1st fixed, 2 nd random, 3rd fixed)
were calculated in three ways. 1.) To determine RT as a function of signal position, we
calculated their mean signal RTs for each position for each of the three within-session
blocks of sequences collapsed over all sessions in each phase. We separately analyzed
rats‟ pre-injection and post-injection data by separate three way ANOVAs (3 groups x 3
sequence blocks x 5 signal positions). 2.) To determine any changes in SRT performance
over training in the pre-and post-injection phases, we calculated each rat‟s mean
normalized signal RT for each within-block of sequences (collapsed over signal
positions) for each successive block of three sessions (5 blocks). We conducted a
separate three-way ANOVA (3 groups x three sequences x five blocks) for each phase to
determine whether patterns of post-injection SRT differed from those found in the preinjection phase. 3.) Finally we calculated each rats mean normalized signal RT for each
within-session block of sequences collapsed over signal position and sessions that
allowed us to directly statistically compare data from pre-and and post-injection phases
as a function of groups and sequence type. We carried out a three-way ANOVA (3
groups x 3 sequences x 2 injection phases).
1.) Signal RT as a function of Signal Position and Sequence. Figure 9
summarizes data describing these functions during the pre-injection phase. These data
were collapsed over groups because as expected no significant effects for this factor were
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uncovered. A similar summary of the post-injection data are also not shown for reasons
already discussed. As seen in this figure and supported by significant main effect for
sequence, F (2, 42) = 25.453, p < 0.001, rats developed longer RTs during the middle
within-session blocks of random sequences than during either of the within-session
blocks of fixed sequences. Rats also reduced their RTs over signal positions within each
within-sessions block of sequences but demonstrated greater declines during the fixed
than random sequence blocks. These observations were confirmed by a significant main
effect for signal position, F (4, 84) = 21.365, p < 0.001, and a significant interaction
between sequence and signal position, F (8, 168) = 12.214, p < 0.001.
2.) Signal RT as a function of sequence type and successive 3-session blocks.
Figures 10A and 10B summarize mean signal RTs for each sequence condition for each
group over successive three-session blocks during the pre- and post-injection phases
respectively. During the pre-injection phase, as seen in Figure 10 A and confirmed by a
main effect for blocks of sessions, F (4, 84) = 4.380, p = 0.003, rats decreased their RTs
over blocks during each type of session. Their decline within the random sequences
appeared somewhat less steep but this observation was not statically supported by any
interaction between blocks and sequence type, F (8, 168) =1.067, p = 0.388. A
significant main effect for sequence type, F (2, 42) = 18.560, p < 001, not surprisingly
replicated that seen in the initial analysis. As seen in Figure 10B, rats no longer
displayed any further declines in signal RTs over post-injection blocks of sessions but
continued to display greater RTs during random than fixed sequences as confirmed by a
significant main effect for sequence type, F (2, 42) = 22.189, p < 001. No significant
interaction between block and sequence was obtained, F (1, 16) = 1.561, p = 0.140. Of
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particular importance is that fact no obvious overall differences between groups were
observed during this phase nor did group significantly interact with sequence, F (4, 42) =
0.531, p = 0.714.
3.) Pre-injection vs post-injection RT comparisons as functions of group and
sequence type. Figure 11 shows the overall mean RT for each group during each phase
as a function of sequence type. We note that no apparent or significant effects for groups
were obtained for this analysis, F (16, 168) = 0.927, p = 0.540. The only apparent effect
was that rats displayed generally lower RTs in the post-injection phase but this
observation was not supported by main effect for phase, F (4, 42) = 0.587, p = 0.674.
Number of Errors
Error rates were either omissions or incorrect nose pokes (to an unlit key in the
presence of a lit key). The means of each rat‟s error rates for each type of error for each
within-session block of sequences (1 st fixed, 2 nd random, 3rd fixed) were calculated. We
calculated mean number of incorrect choices and mean number of omissions for each of
the three within-session blocks of sequences collapsed over all sessions in each phase.
We separately analyzed rats‟ pre-injection and post-injection data by separate three way
ANOVAs (3 groups x 3 sequence blocks x error type). This was done for both omissions
and incorrect choices separately. To determine any changes in SRT performance over
training in the pre-and post-injection phases, we calculated each rat‟s mean errors for
each type for each within-block of sequences for each successive block of three sessions
(5 blocks). We conducted a separate three-way ANOVA (3 groups x three sequences x
five blocks) for each phase to determine whether patterns of post-injection SRT differed
from those found in the pre-injection phase.
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There were significantly more omissions compared to incorrect choices, as shown
in Figure 12: F (2, 18) = 17.843, p = 0.00. As shown in Figure 13A, when analyzing
omissions in more detail in the pre-injection phase, the 15 sessions were broken down to
three-session blocks. ANOVA was conducted for 3 (groups) by 3 (sequence conditions)
by 5 (three-session blocks). Results were not significant for blocks: F (4, 84) = 0.690, p =
0.601. The same analysis was conducted for post-injection data, as shown in Figure 13B.
Similarly, results were again not significant for blocks: F (16, 168) = 1.226, p = 0.253;
however, sequence was found to be significant: F (2, 42) = 4.367, p = 0.019. An in-depth
analysis of the sequence types revealed that the rats made significantly fewer omissions
during their first fixed sequence than during the random sequence or the final fixed
sequence, Fs (2, 21) = 8.891; 6.969, p = 0.007; 0.015. Differences in omissions between
the random and third fixed sequence were not significant, F (2, 21) = 1. 032, p = 0.321.
As shown in Figure 14, when directly comparing omissions between the pre-injection and
post-injection phases, no significant interactions among sequence type, group, and
blocks: F (4, 42) = 1.359, p = 0.264 occurred but a main effect for sequence type was
significant: F (2, 42) = 4.170, p = 0.022.
When looking at three-session blocks (acquisition data for incorrect responses for
preinjection, as shown in Figure 15A), results were not significant for sequence type and
groups: F (16, 168) = 1.594, p = 0.075. Sequence type was significant: F (2, 42) =
12.450, p = 0.000. The same analysis was performed for post-injection data, as shown in
Figure 15B. No significant results were obtained for blocks: F (4, 84) = 0.817, p = 0.518.
Sequence type however was found to be significant: F (2, 42) = 17.907, p = 0.000. An indepth analysis of sequences for postinjection data revealed a significant effect for the
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random sequence and overall significant decline in the mean number of incorrect choices
over blocks: F (4, 84) = 2.846, p = 0.029. In addition, a separate analysis within each
block of sequences revealed a significant effect for group in the first fixed sequence: F (2,
42) = 6.826, p = 0.005. There were more errors with the paraquat and water group
compared to the other groups (saline group and paraquat and CoQ10 group).
When comparing omissions between the two phases, pre injection and post
injection, as shown in Figure 16, there were no significant interactions among sequence
type, group, and blocks: F (16, 168) = 0.919, p = 0.549. Again, sequence type was found
to be significant: F (2, 42) = 16.871, p = 0.00. There were more errors for the random
sequences versus the fixed sequences. These tests may not have sufficient power to detect
group differences.
Histochemistry
Histochemical assays from Phase 3 are not yet available from Facecchia‟s
master‟s thesis (2011) at the University of Windsor biochemistry department.
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CHAPTER V
DISCUSSION
Although considerable evidence has shown that the development of PD is a result
of a gene–environment interaction, exposure to environmental toxins has been a major
focus in current research (Di Monte, 2003). In particular paraquat (PQ), a herbicide, has
been linked to the incidence and progression of PD (Castello, 2007). The current study
was designed in part to assess a PQ-induced model of PD in Long-Evans hooded rats and
to evaluate the neuroprotective properties of water-soluble coenzyme Q10 using the serial
reaction time task. Reaction time and error (omissions and incorrect choices) were
measured as a function of sequence structure.
In the SRT task, when the location of stimuli followed a repeated fixed sequence,
rats‟ reaction times decreased dramatically. The improvement of reaction time over trials
in the same session was due to learning of the specific sequence. However, the same
improvement occurred for the random sequences. In the random condition, the individual
stimulus–response relations do not allow prediction of subsequent ones, but in the fixed
condition, stimulus-response relations are highly predictive. Thus, it can be assumed that
enhanced performance under sequential conditions reflects the establishment of a higherorder motor plan (Hoffmann & Koch, 1998). Domenger and Schwarting (2007) interfered
with these cognitive mechanisms through violations of well-trained sequences by
replacing only one specific position in the FR schedule. They found that the major effect
of this violation was an increase in reaction times at the violated position. These findings
suggested that the SRT was an automated task but still required some attention to the
ongoing stimuli. This method of introducing violations might be of importance when
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using this task in neurodegenerative disorders. It might show strong effects between the
disorder of interest and the placebo group.
Important methodological differences exist between human and nonhuman
preparations. In SRT task experiments with humans, the experimenter can use verbal
instructions to communicate to the subjects, encouraging them to perform the task as
quickly and accurately as possible. This cannot be done with nonhuman subjects where
the experimenter must communicate the objectives nonverbally. With the development of
a simple paradigm of studying SRT, variations in methodology make comparisons among
studies difficult. For example, simple parametric manipulations, such as varying the
response to stimulus interval, can influence the amount of learning (Willingham et al.,
1997) (i.e., if this interval was too long, these animals do not express learning). Evidence
suggests that multiple forms of representations exist even within implicit learning (Seger,
1998). A study by Heindel et al. (1989) demonstrated a double dissociation between
patients with Huntington‟s disease and patients with Alzheimer‟s disease in implicit
motor learning and implicit perceptual learning. Heindel and colleagues suggested that
deficits in the motor learning task were correlated with the amount of dementia in these
patients, which suggests that implicit learning can affect multiple levels and different
neural structures.
For phase 3, when comparing the different groups, (a) paraquat and WS- CoQ10,
(b) paraquat and H2O, and (c) saline and H2O, there were no RT differences among
groups . There are several possibilities why this might have occurred. One possibility is
that not enough paraquat reached the CNS to kill enough dopaminergic neurons in the SN
region. The second possibility could be that five weeks was not enough time to cause cell
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death in these rats. Lastly, the therapeutic effects of the neuroprotectant, WS- CoQ 10, may
not have been observed due to the short period of administration to the rats.
Parkinson‟s disease (e.g., tremor, impaired facility of movement, rigidity, and loss
of postural reflexes) allows for the possibility that patients with PD are capable of
sequence learning but are simply unable to demonstrate this learning through a decrease
in reaction time over trials (Westwater et al., 1998). One concern of using the motor
version of the SRT task is that the performance of PD patients may be seriously
compromised by the motor difficulties that characterize this disease. This study examined
the performance of patients with PD (n=13) and healthy controls (n=11), matched for
verbal fluency on a verbal version of the SRT task, where the standard button-pressing
response was replaced by a spoken response. They found that the PD group demonstrated
less sequence learning than the controls, independent of age and severity of illness.
Evaluation of the PQ-Induced PD Model and Susceptibly of the SN
Five injections of PQ (10 mg/kg) or placebo was injected into the rats. No
fatalities were reported. An important aspect to consider in the effectiveness of the fiveinjection regime was to determine whether the amount of PQ administered to the rats was
enough to selectively target and cause neuronal cell death in the substantia nigra while
leaving other brain regions and organs unharmed. Unfortunately, due to technical
difficulties, these staining results were not obtained (Facecchia, 2011, pending thesis).
However, previous research found that PQ selectively targets dopaminergic neurons in
the substantia nigra by exerting its toxic effects through the production of ROS (DinisOliveira et al., 2006). Several authors have suggested that DA neurons are susceptible to
the oxidative damage caused by toxins due to pre-existing vulnerabilities in the neurons.
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Dopaminergic neurons are already under considerable oxidative stress because the
metabolisation of dopamine involving MAO produces hydrogen species (H 2 O2) as a byproduct (Dinis-Oliveira et al., 2006). Furthermore, H 2O 2 is converted by Fenton reactions
to produce highly toxic hydroxyl radicals in the presence of the high levels of iron
usually present in the SN (Youdmin et al., 1989). Postmortem analysis of PD patients has
confirmed the presence of high levels of iron in the substantia nigra (Dexter et al., 1989).
It is evident that PQ-induced redox cycling within the SN may exceed the oxidative
defences of the DA neurons, thus proving detrimental for the neurons.
Although rodent models are advantageous because subjects are easily accessible,
a varied susceptibility exists between species in their response to neurotoxins. For
example, mice are more susceptible to MPTP than rats. Furthermore, age, gender, and
body weight also play important roles in determining the sensitivity of an animal to
neurotoxins (Przedborski & Vila, 2001). Differences have also been found among
different strains of rats. For example, Lewis rats require two-fold higher dosing of
oxidopamine than Fischer or Sprague-Dawley rats. Interestingly, when rotenone is
administered in Lewis rats, less variability and more consistency are exhibited compared
to Sprague-Dawley rats (Betarbet et al., 2002). Evidence of neuroprotection in rodents
does not guarantee similar results in humans (Emborg, 2004). The advantage of using an
animal model is to obtain a phylogenetic perspective about the odds of success when
translating a therapy to humans. Obviously these models must continue to be refined in
order to improve techniques for evaluating neuroprotective compounds.
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WS- CoQ10 as a Therapeutic Agent in Rats
Coenzyme Q10 is a hydrophobic and is localized in the inner mitochondrial
membrane. Previous studies have used oil formulations of CoQ 10 . Since CoQ10 is very
hydrophobic, cells cannot absorb it easily. Recently, water-soluble CoQ10 containing both
the oxidized and reduced forms was formulated and prepared by Drs. M. Sikorska and H.
Browhy-Borowski. Water formulations of CoQ10 are readily absorbed by the cells when
added to tissue culture media, making it possible to study the mechanism by which CoQ 10
offers protection against oxidative stress. An increase in CoQ 10 content in the
mitochondrial membranes and cell membranes has been observed in cells pre-treated
with CoQ10 (Sandhu et al., 2003). WS- CoQ10 may be exerting its neuroprotective effects
by acting as an antioxidant and reducing the amount of harmful reactive oxygen species
by scavenging free radicals (Beal et al., 2003). In vivo studies have shown the ability of
the enzyme to prevent the reduction of ATP levels. Clinical trials have evaluated oilsoluble CoQ10 in PD patients and found a fair amount of absorption and tolerance of
CoQ10 but cautioned that very high doses were needed to achieve any positive effects
(Shults et al., 2004). However, no efficacy trials have proved that CoQ 10 stabilizes
symptoms of PD with this other formulation. WS- CoQ10 is an improved formulation, as
it is a stable water-soluble complex that can be administered orally. Sikorska et al. (2003)
found elevated plasma levels of WS- CoQ10 in rats fed with this compound.
One of the major objectives of this study was to assess the neuroprotection
provided by WS- CoQ10 as a therapeutic agent in rats. Data from Facecchia (2011,
pending thesis) have yet to be obtained.
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Susceptibility of Rats to PQ Toxicity and Protection by WS- CoQ10
In the current study, the susceptibility of paraquat toxicity in rats are being
assessed by another colleague participating in this project. To data these results have not
been obtained. However, in previous studies, Saint-Pierre and colleagues (2006) found a
significant loss of DA neurons observed in the SNc after 6 weeks of only two toxin
injections (30 mg/kg) in 6-month-old rats. Shultz and colleagues (1999) have attributed
the greater effectiveness of CoQ10 in aged animals as a result of the decline in brain levels
of CoQ10 with age. The decline of CoQ10 levels can be attributed to reduced synthesis of
age-dependent increase in lipid peroxidation (Beyer et al., 1985).
Challenges Associated in Finding a Neuroprotective Therapy for PD
There are limitations to current models used for neuroprotection. Cell cultures are
used in a variety of research. They are especially important when drugs are first tested to
determine whether they can protect cells from a variety of toxins. Cell culture models do
not provide insight into how a drug will behave in an organism. To evaluate the capacity
of drugs to protect DA neurons from toxic insults, its side effects and treatmentassociated complications in vivo models are indispensable.
One of the challenges in developing neuroprotective strategies is that the exact
causative factors of PD remain unclear. Most cases of PD are sporadic and of unknown
etiology. Knowing the precise mechanism of PD would then allow the identification of
probable targets for the development of neuroprotective agents (Olanow et al., 2008).
Which, if any, of the proposed mechanisms in PD is primary and is responsible for cell
death remains uncertain. As discussed earlier, many mechanisms cause cell death in PD.
Studies have shown that patients carrying the same gene mutation and who are family
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members may exhibit different clinical symptoms and different pathology (Olanow et al.,
2008), implying that a combination of various neuroprotectants acting simultaneously on
different mechanisms might be required to achieve neuroprotection.
Future Work
In future studies, the present test might be useful to study and distinguish brain
mechanisms critical for skill and attention. Electrophysiological and brain imaging
studies have shown that sequential learning and performance are correlated with a
number of changes in neuronal activity, including basal ganglia structures, cerebellum,
and various cortical areas, especially within the motor cortex ( Keele et al., 203; SaingCyr 2003). The use of violations in humans yield activations in the basal ganglia as
shown in the fMRI (Huettel et al., 2002). A role of the basal ganglia has also been
specifically demonstrated with lesion studies in rodent models using the SRT (Keel et al.,
2003). The use of this SRT task in Parkinson‟s disease may be of value since impaired
sequential learning reflects the loss of dopamine function within the basal ganglia.
Due to the lack of histochemical results, we cannot conclude that there was any
neuroprotection by CoQ10 or if paraquat did indeed cause a loss of dopamine neurons in
these rats. Once a standard protocol has been developed to count the cells in the brain
tissue of rats, it would be beneficial to run this test again to see whether there was any
neuroprotection by CoQ10 using the SRT.
Therapy for PD begins after diagnosis, by which time a large number of DA
neurons have already been lost. For a candidate to be considered as a good
therapeutic/restorative agent, it should be able to arrest the further loss of neurons and
thereby prevent the progression of this disease. Further experiments will be needed to
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confirm our studies aimed at evaluating the potential effects of WS- CoQ 10 as a
therapeutic intervention in PD. Since PD is a slowly progressive disease, it would be
important to have a longer-term follow-up of these rats in the SRT task. This follow-up
may be needed to identify clinically meaningful benefits to the administration of WSCoQ10 .
WS- CoQ10 is now being developed to cross the blood–brain barrier (BBB), an
evaluation of the amount of WS- CoQ10 that diffuses across the BBB and furthermore,
the amount taken up by the mitochondria would be helpful findings. More research is
required in this area. The next steps would be to determine if this compound is safe for
human consumption, as this would be a potential candidate for clinical trials.
Conclusion
It is of value to have an animal model of a human implicit memory task for which
there is already reasonable evidence in humans that it reflects a motor skill. In the current
study, rats were more efficient on 5CSRT under fixed rather than random sequences for
RTs and incorrect choices. This effect occurs for RTs as a function of signal position and
also when collapsed over positions.
While we did not demonstrate significant RT differences between the
neuroprotected group and the non-neuroprotected group, it remains an open question as
to whether this represents a true absence of learning differences between the groups or
rather a problem of sensitivity of our testing methods. Repeating this study with probe
sequences containing single violations might produce more reliable effects as a function
of PQ-induced neurodegeneration similar to that reported by Eckart et al (2010). The fact
that our PQ+H2O group did produce more incorrect choices during the first third or each
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session than the other two groups is interesting and needs to be replicated in further
research. The questions we need to determine are whether such a difference resulted
from the inclusion of random sequences mid-way through the session or if it merely
reflects poorer performance at the beginning of a session. The fact that this effect
emerged over blocks suggests that neuro-degeneration of domapine areas may have
continued to progress in these animals but was halted by post-injection treatment with
WS-CoQ10.
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FIGURES

Figure 1. Motor components of the human basal ganglia (Purves 2001). Coronal section
through the brain showing anatomical locations of structures involved in the basal ganglia
pathway. Most of these structures are in the telencephalon, although the substantia nigra
is in the midbrain and the thalamic and subthalamic nuclei are in the diencephalon.
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Figure 2A. The basal ganglia circuitry: the direct pathway (Purves 2001).
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Figure 2B. The basal ganglia circuitry: the indirect pathway (Purves 2001).

Figure 3. Catecholamine synthesis. Dopamine functions as both a neurotransmitter and a
precursor for other catecholamines (Wurtman 1980).
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Figure 4. The oxidized and reduced forms of CoQ10 (Chew 2004).
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Figure 5. Serial reaction time task operant chamber.

Figure 6. Nose Poke Key Locations
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Figure 7. Rat groupings based on the injection regime and water supplementation.

Figure 8. Schematic outline for the three phases.
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Figure 9. Normalized average RTs plotted as a function of sequence for each signal
position over pre-injection trials.
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Figure 10. Rats‟ acquisition curves for normalized average RTs plotted as a function of
sequence for 3-session blocks.
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Figure 11. Normalized average RTs plotted for both pre-injection and post-injection
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Figure 12. Overall error data for both misses and incorrect choices as a function of
sequence.

68

Figure 13. Rats‟ acquisition curves for mean number of omissions as a function of
sequence structure over 3-session blocks.
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Figure 14. Mean number of omissions for both pre and post-injection as a function of
sequence
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Figure 15. Rats‟ acquisition curves for mean number of incorrect choices as a function of
sequence structure over 3-session blocks.
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Figure 16. Mean number of incorrect choices for both pre and post-injection as a
function of sequence.
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